Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atorvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 10/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 2/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | RHOC | P08134 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.87 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.87 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.87 |
| ▸ | PDE6D | O43924 | 3/20 | 0.77 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21637576 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3056792 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL537781 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL4201645 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL13900412 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL465015 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL8257670 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3831 | 1.00 | HMGCR (1.00) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL3930191 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 | |
| Atorvastatin SCHEMBL7037657 | 0.99 | HMGCR (0.98) | HMGCRSLCO1B1ABCB11HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102716068-A | Method for carrying therapeutic substances into cells | MAGFORCE NANOTECHNOLOGIES AG | 2012-10-10 | — | — | CN | claimed |
| CN-119587702-A | Pharmaceutical composition capable of improving bioavailability of oral statin drugs and application thereof | 强生化学制药厂股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-3642261-A1 | BLOCK-COPOLYMERS FOR THE DELIVERY OF ACTIVE AGENTS | Julius-Maximilians-Universität Würzburg (DE) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018234329-A1 | BLOCK-COPOLYMERS FOR THE DELIVERY OF ACTIVE AGENTS | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2018-12-27 | — | — | WO | disclosed |
| US-9649366-B2 | Manufacturing and purification processes of Complex protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Antitrypsin (A1AT) or a combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins | HOANG KIEU (US) | 2017-05-16 | — | — | US | disclosed |
| WO-2016162886-A1 | HCQS FOR PROPHYLAXIS AND TREATMENT OF STATIN INDUCED DIABETES | IPCA LABORATORIES LIMITED (IN) | 2016-10-13 | — | — | WO | disclosed |
| US-20140142284-A1 | Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins | HOANG KIEU (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140140987-A1 | Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins | HOANG KIEU (US) | 2014-05-22 | — | — | US | disclosed |
| CN-102949535-A | Chinese herbal preparation resistant to hyperlipidemia and atherosclerosis and preparation method of Chinese herbal preparation | SUZHOU TONGLI MEDICAL TECHNOLOGY CO LTD | 2013-03-06 | — | — | CN | disclosed |
| WO-2005097191-A2 | COMBINATIONS COMPRISING (S)- AMLODIPINE AND A HMG-CoA REDUCTASE INHIBITOR OR CHOLESTEROL ABSORPOTION INHIBITOR OR BOTH, AND METHODS FOR REDUCING HYPERTENSION | SEPRACOR INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2000069446-A1 | COMBINATION THERAPY FOR TREATING HYPERCHOLESTEROLEMIA | GELTEX PHARMACEUTICALS, INC. (US) | 2000-11-23 | — | — | WO | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140987-A1 | Manufacturing and Purification Processes of Complex Protein found in Fraction IV to make a separated Apo, Transferrin, and Alpha 1 Anti strepsin (A1AT) or A combined Transferrin/Apo/Human Albumin/A1AT and all new found proteins | SERPINC1, HBG1, APOB | HMGCR 1471/4885SLCO1B1 4671/4885ABCB11 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.